Login
Open Demat Account
Open Demat A/C
Offerings
+
Research
Markets+
Talking Finance+
Support+
Media+
Partner Us+
Trade LoginReports LoginIFD Partner Login
Demo
Close Language Tab
Locate us
Languages
  • Home
  • Company Information
  • Ipca Laboratories Ltd
I
Ipca Laboratories Ltd Pharmaceuticals
₹ 1,529.50 +41.00 (2.75%)
  • NSE
  • BSE

Overview

  • BSE Code 524494
  • NSE Symbol IPCALAB
  • ISIN Demat INE571A01038
  • Book Value (₹) 271.64
  • Face Value (₹) 1.00
  • Market Cap (₹ Cr.) 37,307.21
  • P/E (TTM) 45.48
  • EPS (TTM) 32.33
  • Div Yield (%) 0.27

Performance

Today’s Low 1,479.10
Today’s High 1,560.50

1,529.50
52W Low 1,168.20
52W High 1,755.90

1,529.50
Open 1,488.00
Prev. Close 1,488.50
Volume 90,330.00

Corporate Actions

IPCA Laboratories Limited - Certificate under SEBI (Depositories and Participants) Regulations, 2018
Apr 07, 2025

The Company has enclosed herewith certificate received from RTA under Reg 74 (5) SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31.03.2025

About Ipca Laboratories Ltd

Ipca Laboratories is involved in the manufacturing and marketing of pharmaceuticals. The company came into existence as as  `The Indian Pharmaceutical Combine Association Limited' in 1949. The company has changed its name several times. At first, it changed its name to `Ipca Laboratories Ltd. in 1964. Two years later, in 1966, it changed its name to Ipca Laboratories Private Limited. In 1988, it again changed its name to Ipca Laboratories Ltd in 1988. The company established a modern plant at Athal, Silvassa, for the manufacturing of pharmaceutical formulations in 1994. It launched a new domestic marketing division, ACTIVA, dedicated to Rheumatology Care in 2003. Ipca continued its inorganic growth in 2005 by acquiring the Cardiac brand ISORDIL from Wyeth Limited. In the same year, it finished its merger with Innotech Pharma Limited. In 2008, Ipca Laboratories received US FDA approval for Propranolol Hydrochloride Tablets. Ipca Laboratories received approval from the UK Medicines and Healthcare Products Regulatory Agency for its 4th manufacturing unit at a Special Economic Zone in Indore for good manufacturing practices under the regulator in 2011. The company finished the acquisition of a High Potency Oral Solid Dosage formulations manufacturing unit situated at Pithampur near Indore in 2014. It gained complete control of a 100% stake in Ramdev Chemical Private Limited in 2019. In 2022, the company commenced a new green field manufacturing unit being set up at Dewas (Madhya Pradesh).

Business Segments

  • APIs:The organization manufactures 80+ APIs at 12 production facilities, accounting for nearly 25% of its turnover. The organization’s leadership extends across the manufacturing of Atenolol (anti-hypertensive) and Chloroquine Phosphate (anti-malarial).
  • Formulations:Under this segment, it manufactures 350+ formulations in almost every dosage form, with 4 of its branded formulations. It is a leader in Pain, Rheumatology, Antimalarials and Haircare therapies with a steadily growing portfolio.
  • Global Business:The company has a rich presence across the UK, the USA and Russia. It administers its USA business through Bayshore Pharmaceuticals LLC.
Subsidiary As of 2022, the company had 11 subsidiaries and a few of them are listed below:
  • Ipca Laboratories (U.K.) Ltd:It is a wholly-owned subsidiary which came into existence as to apply for and obtain product registrations in the United Kingdom.
  • Ipca Pharmaceuticals, Inc. USA:It is a wholly-owned subsidiary that coordinates the development and registration of formulations developed by Ipcs in the USA as well as the distribution of Active Pharmaceutical Ingredients (APIs) manufactured in the US market.

Key Personnel

Ajit Kumar Jain, Managing Director & CFO Mr A. K. Jain is a Chartered Accountant and a Science Graduate and has been with the company since 1981. He was inducted into the company as a financial controller. He holds a rich experience of over 30, including 29 years in the pharmaceutical industry. Mr. Jain was first appointed to the Board as an Executive Director in 1994.

Corporate Actions

The company has no history of bonus issues, stock splits and other corporate actions.
Founded: 1949
Chairman: Premchand Godha
Managing Director: A K Jain
Address: 48 Kandivli Industrial Estate, Kandivli (West), Mumbai, Maharashtra, 400067,
HO Tel: 91-022-66474747